PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
0.79%
Growth of 0.79% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
-28.77%
Cost reduction while Drug Manufacturers - Specialty & Generic median is -4.56%. Seth Klarman would investigate competitive advantage potential.
66.19%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.20%. Joel Greenblatt would investigate competitive advantages.
64.88%
Margin expansion exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.19%. Joel Greenblatt would investigate competitive advantages.
-72.57%
R&D reduction while Drug Manufacturers - Specialty & Generic median is -6.20%. Seth Klarman would investigate competitive implications.
6.30%
G&A change of 6.30% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
16.10%
Marketing expense change of 16.10% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
119.87%
Other expenses change of 119.87% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
7.55%
Operating expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
-16.92%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is -6.64%. Seth Klarman would investigate advantages.
-35.94%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
168.49%
D&A change of 168.49% versus flat Drug Manufacturers - Specialty & Generic D&A. Walter Schloss would verify adequacy.
107.32%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 15.95%. Joel Greenblatt would investigate advantages.
-35.86%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 7.00%. Seth Klarman would investigate causes.
131.77%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 19.51%. Joel Greenblatt would investigate advantages.
131.53%
Operating margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 12.28%. Joel Greenblatt would investigate advantages.
67.77%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.46%. Jim Chanos would check for issues.
96.02%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 24.38%. Joel Greenblatt would investigate advantages.
96.05%
Pre-tax margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.73%. Joel Greenblatt would investigate advantages.
165.32%
Tax expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 38.65%. Jim Chanos would check for issues.
94.53%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 24.78%. Joel Greenblatt would investigate advantages.
94.58%
Net margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.74%. Joel Greenblatt would investigate advantages.
94.63%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 26.92%. Joel Greenblatt would investigate advantages.
94.63%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 26.92%. Joel Greenblatt would investigate advantages.
0.77%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would check for issues.
0.77%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.06%. Jim Chanos would check for issues.